TARA Stock Analysis: Buy, Sell, or Hold?
TARA - Protara Therapeutics, Inc. Common Stock
$3.97
0.05 (1.28%)
▲
5d:
-1.73%
30d:
-2.22%
90d:
-25.38%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 10, 2026
5d
Get Alerted When TARA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TARA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TARA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TARA is currently trading at $3.97, which is considered slightly low relative to its 30-day fair value range of $3.95 to $4.18.
Technical Outlook: Technically, TARA is in a strong downtrend. Immediate support is located at $3.77, while resistance sits at $4.14.
Market Sentiment: TARA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.57 (+569.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TARA is in a strong downtrend. Immediate support is located at $3.77, while resistance sits at $4.14.
Market Sentiment: TARA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.57 (+569.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.95 -
$4.18
Company Quality Score
47/100
(HOLD)
Options IV Signal
23th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 23th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 569.3% below Wall St target ($26.57)
Trading Range Analysis
30-Day Trading Range
$3.95 -
$4.18
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.62
(15.5%)
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$4.14
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.41
Wall Street Target
$26.57
(+569.3%)
Share & Embed Analysis
Last updated: August 03, 2026 10:30 PM ET
Data refreshes hourly during market hours. Next update: 11:30 PM
Data refreshes hourly during market hours. Next update: 11:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacqueline Zummo
SELL
1134 shares
2026-04-08
Jacqueline Zummo
SELL
22598 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
